Biohaven Pharmaceuticals, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $3.9B

Website

Clinical Trials

Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)

Conditions: SCA
Spinocerebellar Ataxias

First Posted Date: 2023-09-13

Last Posted Date: 2024-11-05

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Registration Number: NCT06034886

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

Phase 3

Active, not recruiting

Conditions: SMA
Neuromuscular Diseases
Spinal Muscular Atrophy

Interventions: Drug: Placebo
Drug: taldefgrobep alfa

First Posted Date: 2022-04-20

Last Posted Date: 2023-11-07

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 269

Registration Number: NCT05337553

Locations: 🇺🇸
CHOP Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇨🇿
Motol University Hospital, Prague, Czechia
🇪🇸
Maternal-Child'S Hospital of Málaga, Regional University Hospital - Pediatric Neurology Unit, Málaga, Spain

and more 50 locations

Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)

Conditions: Multiple System Atrophy (MSA)

First Posted Date: 2021-10-20

Last Posted Date: 2022-10-06

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Registration Number: NCT05086094

Locations: 🇺🇸
PPD, Morrisville, North Carolina, United States

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Phase 3

Conditions: Obsessive Compulsive Disorder

Interventions: Drug: Troriluzole (BHV-4157)

First Posted Date: 2021-01-14

Last Posted Date: 2024-12-10

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 1200

Registration Number: NCT04708834

Locations: 🇺🇸
CalNeuro Research Group, Los Angeles, California, United States
🇺🇸
Clarity Clinical Research, Los Angeles, California, United States
🇺🇸
University of Chicago Department of Psychiatry & Behavioral Neuroscience, Chicago, Illinois, United States

and more 172 locations

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

Phase 3

Recruiting

Conditions: Obsessive-Compulsive Disorder

Interventions: Drug: Placebo
Drug: Troriluzole

First Posted Date: 2021-01-05

Last Posted Date: 2024-04-19

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 700

Registration Number: NCT04693351

Locations: 🇺🇸
Om Research LLC, Lancaster, California, United States
🇺🇸
CI Trials, Riverside, California, United States
🇺🇸
Clintex Research, Miami, Florida, United States

and more 107 locations

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Phase 3

Recruiting

Conditions: Obsessive-Compulsive Disorder

Interventions: Drug: Troriluzole
Drug: Placebo

First Posted Date: 2020-11-23

Last Posted Date: 2025-01-09

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 700

Registration Number: NCT04641143

Locations: 🇺🇸
Global Clinical Trials, Costa Mesa, California, United States
🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 82 locations

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Combination Product: CIML NK Cells plus KP1237 and low dose IL-2

First Posted Date: 2020-11-18

Last Posted Date: 2024-10-11

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 25

Registration Number: NCT04634435

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of BHV-3241 in Participants With Multiple System Atrophy

Phase 3

Completed

Conditions: Multiple System Atrophy

Interventions: Drug: Verdiperstat
Drug: Placebo

First Posted Date: 2019-05-16

Last Posted Date: 2023-09-29

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 421

Registration Number: NCT03952806

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 45 locations

Randomized Trial of Adult Participants With Generalized Anxiety Disorder

Phase 3

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Drug: Troriluzole
Drug: Placebo

First Posted Date: 2019-02-04

Last Posted Date: 2024-05-08

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 881

Registration Number: NCT03829241

Locations: 🇺🇸
CalNeuro Research Group, Los Angeles, California, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Boston Clinical Trials, Boston, Massachusetts, United States

and more 45 locations

Troriluzole in Adult Subjects With Spinocerebellar Ataxia

Phase 3

Active, not recruiting

Conditions: Spinocerebellar Ataxia Type 1
Spinocerebellar Ataxia Type 2
Spinocerebellar Ataxia Type 3
Spinocerebellar Ataxia Type 6
Spinocerebellar Ataxia Type 7
Spinocerebellar Ataxia Type 10
Spinocerebellar Ataxias
Spinocerebellar Ataxia Type 8

Interventions: Drug: troriluzole
Drug: Placebos

First Posted Date: 2018-10-10

Last Posted Date: 2024-01-25

Lead Sponsor: Biohaven Pharmaceuticals, Inc.

Target Recruit Count: 218

Registration Number: NCT03701399

Locations: 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 20 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy